[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"TiSport, Llc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":74},{"warningLetters":4,"total":73},[5,30,51],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},732,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-05T04:00:00Z\">08\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-25T04:00:00Z\">07\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsnusportcom-713503-07252025\">snusport.com\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>snusport.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@snusport.com\"> info@snusport.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@snusport.com\"> support@snusport.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 25, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.snusport.com and determined that nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotinetake-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: Zyn Slim Violet Licorice 9mg and Zyn Slim Red Fruits 6,5mg.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as ecommerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502316, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Ascio Technologies, Inc. Danmark\u003Cbr>abuse@ascio.com\u003C\u002Fp>\u003Cp>Google LLC\u003Cbr>google-cloud-compliance@google.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nsnusport.com\n\nSweden\n\ninfo@snusport.com\n\nsupport@snusport.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 25, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.snusport.com and determined that nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotinetake-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: Zyn Slim Violet Licorice 9mg and Zyn Slim Red Fruits 6,5mg.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as ecommerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502316, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA Electronic Mail\ncc:\n(b)(6)\nAscio Technologies, Inc. Danmark\nabuse@ascio.com\nGoogle LLC\ngoogle-cloud-compliance@google.com","snusport.com","snusportcom-713503-07252025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsnusportcom-713503-07252025","2026-10-26T08:10:00.813254+00:00","Warning Letter","Issued","2025-08-05","713503","Tobacco","2026-08-19T16:31:53.057+00:00","VIA Electronic Mail","2025-07-25",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1548,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2024-03-26T04:00:00Z\">03\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-19T04:00:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fammonia-sport-inc-672196-03192024\">Ammonia Sport Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Justin Rapoport\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ammonia Sport Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2045 Cordero Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Del Mar\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92014\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@ammoniasport.com\"> support@ammoniasport.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 19, 2024\u003Cbr>\n\u003Cbr>\nRE: FEI # 3017370207\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Rapoport:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of over-the-counter (OTC) stimulant drug products. The U.S. Food and Drug Administration (FDA) reviewed your website on November 2023 and March 2024 at the Internet address https:\u002F\u002Fwww.ammoniasport.com where your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products are available for purchase in the United States. Based on our review, your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as stimulant drug products.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims from the products’ labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMMONIA SPORT AQUA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…This ammonia inhalant is designed to boost performance in sports!...The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boost of strength, energy, and focus…” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“AQUA Twist and Sniff &gt;Energy &gt;Focus &gt;Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!”… “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.”… “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMMONIA SPORT RAW\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boost of strength, energy, and focus…Uncap, sniff, perform…. ” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“RAW Splash and Sniff &gt;Energy &gt;Focus &gt;Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!” “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.” “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002Fraw\u002F]\u003C\u002Fp>\n\n\u003Cp>“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\u003C\u002Fp>\n\n\u003Cp>(Video advertising Ammonia Sport Raw) “Benefits of “Ammonia Sport” Strength Power Easy Energy boost Focus” [from your Instagram social media account https:\u002F\u002Fwww.instagram.com\u002Fammoniasport\u002F?hl=enh]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMMONIA SPORT SQUEEZE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…This ammonia inhalant is designed to boost performance in sports!...The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boos of strength, energy, and focus…” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“SQUEEZE: Squeeze and Sniff &gt;Energy &gt;Focus &gt;Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!” “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.” “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002Fsqueeze\u002F]\u003Cbr>\n\u003Cbr>\n“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products, containing the ingredients ammonium chloride and sodium carbonate (\"AMMONIA SPORT RAW\") and sodium polyacrylate and ammonium hydroxide (\"AMMONIA SPORT AQUA\" and \"AMMONIA SPORT SQUEEZE\"), are intended for use as stimulant drug products. Specifically, these products are intended for use as both reflex stimulants (i.e., smelling salts, ammonia inhalants) and, more generally, as stimulants to help restore mental alertness or wakefulness. As described below, these stimulant drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the products identified above.\u003C\u002Fp>\n\n\u003Cp>\"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are reflex stimulant drug products subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these reflex stimulant drug products are deemed to be new drugs under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> On June 19, 2008, FDA issued a proposed rule (73 FR 34895)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008 proposed rule is the most recent applicable FDA proposal issued under 21 CFR part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Even if \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" were not marketed as reflex stimulant drug products and were only marketed as more general stimulant drug products, your products would still not meet the requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, stimulant drug products are deemed to be GRASE and not a new drug if, among other things, they conform to the conditions of use in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011), as set forth in the applicable final administrative order.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" stimulant drug products do not conform to the conditions of use specified in Monograph M011 because your products are formulated with the active ingredients ammonium chloride and sodium carbonate (\"AMMONIA SPORT RAW\") and sodium polyacrylate and ammonium hydroxide (\"AMMONIA SPORT AQUA\" and \"AMMONIA SPORT SQUEEZE\"),\u003Csup>\u003Cstrong>\u003Cem>5\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fsup> and are labeled with directions for intranasal administration, neither of which are permitted conditions of use under the deemed final order. Therefore, even if \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" were marketed only as general stimulant drug products, they would not meet requirements under section 505G, under which they would be deemed to be GRASE and not new drugs.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) or are misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330 prior to enactment of the CARES Act. In the case of OTC stimulant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025))\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJustin Rapoport\n\nRecipient Title\n\nOwner\n\nAmmonia Sport Inc.\n\n2045 Cordero Rd.\n\nDel Mar, CA 92014\n\nUnited States\n\nsupport@ammoniasport.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nMarch 19, 2024\n\nRE: FEI # 3017370207\n\nDear Mr. Rapoport:\n\nThis letter concerns your firm’s distribution of over-the-counter (OTC) stimulant drug products. The U.S. Food and Drug Administration (FDA) reviewed your website on November 2023 and March 2024 at the Internet address https:\u002F\u002Fwww.ammoniasport.com where your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products are available for purchase in the United States. Based on our review, your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\n\"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as stimulant drug products.\n\nExamples of the claims from the products’ labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\nAMMONIA SPORT AQUA\n\n“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…This ammonia inhalant is designed to boost performance in sports!...The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boost of strength, energy, and focus…” [from your product label]\n\n“AQUA Twist and Sniff >Energy >Focus >Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!”… “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.”… “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\n\n“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\n\n“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\n\nAMMONIA SPORT RAW\n\n“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boost of strength, energy, and focus…Uncap, sniff, perform…. ” [from your product label]\n\n“RAW Splash and Sniff >Energy >Focus >Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!” “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.” “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002Fraw\u002F]\n\n“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\n\n“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\n\n(Video advertising Ammonia Sport Raw) “Benefits of “Ammonia Sport” Strength Power Easy Energy boost Focus” [from your Instagram social media account https:\u002F\u002Fwww.instagram.com\u002Fammoniasport\u002F?hl=enh]\n\nAMMONIA SPORT SQUEEZE\n\n“Smelling Salts Twist and Sniff!...Ammonia inhalants, also known as smelling salts, are chemical compounds used for arousing consciousness…This ammonia inhalant is designed to boost performance in sports!...The ammonia irritates the blood vessels in the nasal passages providing an instantaneous boos of strength, energy, and focus…” [from your product label]\n\n“SQUEEZE: Squeeze and Sniff >Energy >Focus >Strength.” “What is Ammonia Sport? Our premium smelling salts boost focus, energy, and strength, allowing you to reach your peak performance and get in the game!” “The Most Energy You Will Get From A Smelling Salt” “Our Smelling Salts boost focus, energy, and strength allowing you to reach your peak performance.” “That capsule they hold under their nose are smelling salts, and this pregame\u002Fin-game ritual of athletes using them to get their head in the game is becoming synonymous with elite level performance.“ “-Supports Explosive Energy -Sharp Focus – Maximum Strength – Instant Sensation – Prevents and Treats Fainting” “Made in a FDA registered facility…in FDA approved facilities that meet all cGMP (Current Good Manufacturing Practices) standards.” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002Fsqueeze\u002F]\n\n“(Video showing athletes professional taking product) “You may have seen many League players using smelling salts…they wanna get themselves going…you’re wired. ...try to give him a bit of a boost on the bench…smelling salts makes sure that head is cleared and ready to go…this is my secret weapon…you will go absolutely bizerk” [from your products’ website https:\u002F\u002Fwww.ammoniasport.com\u002F]\n\n“Voted #1 Smelling Salts for Athletes! Athletic Smelling Salts boost strength, energy and focus!” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002FAmmoniaSport\u002F ]\n\nBased on the above labeling claims, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" drug products, containing the ingredients ammonium chloride and sodium carbonate (\"AMMONIA SPORT RAW\") and sodium polyacrylate and ammonium hydroxide (\"AMMONIA SPORT AQUA\" and \"AMMONIA SPORT SQUEEZE\"), are intended for use as stimulant drug products. Specifically, these products are intended for use as both reflex stimulants (i.e., smelling salts, ammonia inhalants) and, more generally, as stimulants to help restore mental alertness or wakefulness. As described below, these stimulant drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the products identified above.\n\n\"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are reflex stimulant drug products subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these reflex stimulant drug products are deemed to be new drugs under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.1 On June 19, 2008, FDA issued a proposed rule (73 FR 34895)2 setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008 proposed rule is the most recent applicable FDA proposal issued under 21 CFR part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.3\n\nEven if \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" were not marketed as reflex stimulant drug products and were only marketed as more general stimulant drug products, your products would still not meet the requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\n\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, stimulant drug products are deemed to be GRASE and not a new drug if, among other things, they conform to the conditions of use in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011), as set forth in the applicable final administrative order.4 However, your \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" stimulant drug products do not conform to the conditions of use specified in Monograph M011 because your products are formulated with the active ingredients ammonium chloride and sodium carbonate (\"AMMONIA SPORT RAW\") and sodium polyacrylate and ammonium hydroxide (\"AMMONIA SPORT AQUA\" and \"AMMONIA SPORT SQUEEZE\"),5 and are labeled with directions for intranasal administration, neither of which are permitted conditions of use under the deemed final order. Therefore, even if \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" were marketed only as general stimulant drug products, they would not meet requirements under section 505G, under which they would be deemed to be GRASE and not new drugs.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, \"AMMONIA SPORT AQUA,\" \"AMMONIA SPORT RAW,\" and \"AMMONIA SPORT SQUEEZE\" are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n______________________\n\n1 Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\n\n2 On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) or are misbranded.\n\n3 FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330 prior to enactment of the CARES Act. In the case of OTC stimulant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025))\n\n5 M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.","Ammonia Sport Inc.","ammonia-sport-inc-672196-03192024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fammonia-sport-inc-672196-03192024","2026-10-26T08:07:55.387894+00:00","2024-03-26","672196","Drugs","Justin Rapoport","2026-08-20T00:12:51.238+00:00","2024-03-19",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":42,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":68,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},1990,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2023-07-18T13:20:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-22T04:00:00Z\">06\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focalsa-transport-logistics-llc-657269-06222023\">Ocalsa Transport &amp; Logistics, LLC\u003C\u002Fa>"," Division of Southwest Imports ","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Omar Cavazos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ocalsa Transport &amp; Logistics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2501 W Military Hwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McAllen\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78503-8955\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Southwest Imports \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 22, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 657269\u003C\u002Fp>\n\n\u003Cp>Dear Omar Cavazos:\u003C\u002Fp>\n\n\u003Cp>On February 23, 2023, and February 24, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Ocalsa Transport &amp; Logistics, LLC located at 2501 W Military Hwy, McAllen, Texas. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form 483a issued on February 24, 2023.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods that you import, including the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Fresh onions, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Fresh Hungaro peppers, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Husk tomatoes, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You import fresh produce that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA has determined that your facility at 2501 W Military Hwy, McAllen, TX 78503-8955 is subject to the food facility registration requirement in section 415 of the FD&amp;C Act [21 U.S.C. § 350d] and our implementing regulation at 21 CFR Part 1, Subpart H. Section 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. Our records indicate that your facility is not currently registered. Failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. 331(dd)].\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility’s owner, operator, or agent in charge, register the facility with FDA within 30 working days of date of this letter. Food facility registration guidance is available online at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions. Registration may be accomplished online at http:\u002F\u002Fwww.access.fda.gov. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 216 West Village Blvd, Suite 107, Laredo, Texas 78041. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 657269 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nOmar Cavazos\n\nRecipient Title\n\nOwner\n\nOcalsa Transport & Logistics, LLC\n\n2501 W Military Hwy\n\nMcAllen, TX 78503-8955\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nJune 22, 2023\n\nWARNING LETTER\n\nRe: CMS # 657269\n\nDear Omar Cavazos:\n\nOn February 23, 2023, and February 24, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Ocalsa Transport & Logistics, LLC located at 2501 W Military Hwy, McAllen, Texas. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form 483a issued on February 24, 2023.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods that you import, including the following foods:\n\nFresh onions, imported from (b)(4), located in (b)(4)\n\nFresh Hungaro peppers, imported from (b)(4), located in (b)(4)\n\nHusk tomatoes, imported from (b)(4), located in (b)(4)\n\nYou import fresh produce that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nIn addition, FDA has determined that your facility at 2501 W Military Hwy, McAllen, TX 78503-8955 is subject to the food facility registration requirement in section 415 of the FD&C Act [21 U.S.C. § 350d] and our implementing regulation at 21 CFR Part 1, Subpart H. Section 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. Our records indicate that your facility is not currently registered. Failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. 331(dd)].\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\nWe request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility’s owner, operator, or agent in charge, register the facility with FDA within 30 working days of date of this letter. Food facility registration guidance is available online at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions. Registration may be accomplished online at http:\u002F\u002Fwww.access.fda.gov. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 216 West Village Blvd, Suite 107, Laredo, Texas 78041. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 657269 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports","Ocalsa Transport & Logistics, LLC","ocalsa-transport-logistics-llc-657269-06222023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focalsa-transport-logistics-llc-657269-06222023","2026-10-26T08:09:36.66246+00:00","2023-07-18","657269","Food & Beverages","Division of Southwest Imports","Omar Cavazos","2026-08-20T00:52:40.101+00:00","Via Express Delivery","2023-06-22",3,{"510k":75,"classification":76,"enforcement":77,"event":78,"event_backfill":79,"pma":80,"warning_letter":81},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]